Amgen Inc. Cash
Amgen Inc. (AMGN) had Cash of $574.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-08-05
- 2026-06-30: Cash $574.00M.
- 2026-03-31: Cash $559.00M.
- 2025-12-31: Cash $604.00M.
- 2025-09-30: Cash $737.00M.
| Period end | Cash | Cash as first filed |
|---|---|---|
| 2026-06-30 | $574.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $559.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $604.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $737.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $542.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $508.00M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $487.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $435.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $489.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $471.00M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $540.00M 10-K · filed 2025-02-14 | |
| 2023-09-30 | $533.00M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $630.00M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $496.00M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $4.97B 10-K · filed 2024-02-14 | |
| 2022-09-30 | $557.00M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $770.00M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $691.00M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $733.00M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $646.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $923.00M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $845.00M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $802.00M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $771.00M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $687.00M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $718.00M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $677.00M 10-K · filed 2021-02-09 | |
| 2019-09-30 | $626.00M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $641.00M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $649.00M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $580.00M 10-K · filed 2020-02-12 | |
| 2018-09-30 | $503.00M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $559.00M 10-Q · filed 2018-07-27 | |
| 2018-03-31 | $502.00M 10-Q · filed 2018-04-25 | |
| 2017-12-31 | $509.00M 10-K · filed 2019-02-13 | |
| 2017-09-30 | $545.00M 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $464.00M 10-Q · filed 2017-07-26 | |
| 2017-03-31 | $465.00M 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $458.00M 10-K · filed 2018-02-13 | |
| 2015-12-31 | $406.00M 10-K · filed 2017-02-14 | |
| 2014-12-31 | $438.00M 8-K · filed 2016-10-31 | |
| 2014-06-30 | $584.00M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $321.00M 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $539.00M 10-K · filed 2015-02-19 | |
| 2013-09-30 | $451.00M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $454.00M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $433.00M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $370.00M 10-K · filed 2014-02-24 | |
| 2012-09-30 | $491.00M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $703.00M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $527.00M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $680.00M 10-K · filed 2013-02-27 | |
| 2011-09-30 | $372.00M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $182.00M 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $191.00M 10-Q · filed 2011-05-10 | |
| 2010-12-31 | $145.00M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $129.00M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | -$115.00M 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $100.00M 10-K · filed 2011-02-25 | -$100.00M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |